% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Weller:272838,
      author       = {M. Weller and E. Le Rhun and M. Van den Bent and S. M.
                      Chang and T. F. Cloughesy and R. Goldbrunner and Y.-K. Hong
                      and R. Jalali and M. D. Jenkinson and G. Minniti and M.
                      Nagane and E. Razis and P. Roth and R. Rudà and G.
                      Tabatabai$^*$ and P. Y. Wen and S. C. Short and M. Preusser},
      title        = {{D}iagnosis and management of complications from the
                      treatment of primary central nervous system tumors in
                      adults.},
      journal      = {Neuro-Oncology},
      volume       = {25},
      number       = {7},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2023-00411},
      pages        = {1200–1224},
      year         = {2023},
      abstract     = {Central nervous system (CNS) tumor patients commonly
                      undergo multimodality treatment in the course of their
                      disease. Adverse effects and complications from these
                      interventions have not been systematically studied, but pose
                      significant challenges in clinical practice and impact
                      function and quality of life, especially in the management
                      of long-term brain tumor survivors. Here the European
                      Association of Neuro-Oncology (EANO) has developed
                      recommendations to prevent, diagnose and manage adverse
                      effects and complications in the adult primary brain CNS
                      tumor (except lymphomas) patient population with a specific
                      focus on surgery, radiotherapy and pharmacotherapy.
                      Specifically, we also provide recommendations for dose
                      adaptations, interruptions and re-exposure for
                      pharmacotherapy that may serve as a reference for the
                      management of standard of care in clinical trials. We also
                      summarize which interventions are unnecessary, inactive or
                      contraindicated. This consensus paper should serve as a
                      reference for the conduct of standard therapy within and
                      outside of clinical trials.},
      keywords     = {Adverse affects (Other) / Dose (Other) / Interruptions
                      (Other) / Prevention (Other) / Re-exposure (Other) /
                      Toxicity (Other)},
      cin          = {TU01},
      ddc          = {610},
      cid          = {I:(DE-He78)TU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36843451},
      doi          = {10.1093/neuonc/noad038},
      url          = {https://inrepo02.dkfz.de/record/272838},
}